Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma – 2 Minute Medicine
|
Chimeric antigen receptor T–cell therapy elicits treatment response in patients with refractory B-cell lymphoma
2 Minute Medicine Both are primarily treated with rituximab-based chemotherapy regimens, however the prognosis for either cancer remains poor for patients that either relapse or are refractory to treatment. Adoptive immunotherapy, which uses T–cells expressing a CAR for … |
